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Background: Diabetes mellitus and metabolic syndrome are the common problems of the modern society.
The interest in herbal medicines increases, and often they are used in combination with conventional drugs.
Aegopodium podagraria L. (goutweed) is a plant widely used in traditional medicine. Hypoglycemic effect of
goutweed aerial part tincture has been previously shown in alloxan-induced diabetic mice and in rats receiving
excess of fructose and hydrochlorothiazide. The effects of co-administration of the tincture with widely used
antihyperglycemic drugs have not been verified. The objective of this study is to determine the efficacy of
goutweed tincture and its combination with metformin using the model reproducing the pathogenetic
mechanisms of the metabolic syndrome and type 2 diabetes.
Methods: The animals were divided into 5 groups, as follows: intact control, dexamethasone (untreated),
dexamethasone +metformin, 50 mg/kg; dexamethasone + A. podagraria tincture, 1 ml/kg intragastrically;
dexamethasone +metformin, 50 mg/kg intragastrically + A. podagraria tincture, 1 ml/kg intragastrically. Dexamethasone
was used at a dose of 5 mg/kg subcutaneously for 5 days. Insulin tolerance test and oral glucose tolerance test were
performed, triglycerides, total lipids, total and HDL cholesterol content in plasma were determined, LDL cholesterol
content was calculated, glycogen content in the liver was measured.
Results: Goutweed tincture combined with metformin increased its effect on the basal glycemia and on the results of
the short insulin test. In the oral glucose tolerance test the lowest area under glucose curve and average glycemia value
were seen in animals receiving this combination. Only metformin tended toward the reduction of liver glycogen. The
decrease in triglycerides and increment of HDL cholesterol content (caused by the tincture), as well as tendency towards
the decrease in total lipids level (caused by metformin) were observed against a background of the investigated
combination, though the ability of GW tincture to reduce LDL cholesterol content and the same tendency seen against
a background of metformin were eliminated when these preparations were administered together.
Conclusion: It has been shown that goutweed tincture combined with the respectively low dose of metformin partially
increases the efficacy of the latter in dexamethasone-treated rats.
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Background
In recent years much attention has been paid to the im-
provement of the therapy of metabolic syndrome and
type 2 diabetes. The total number of people with dia-
betes is projected to rise from 171 million in 2000 to
366 million in 2030 [1]. Among the drugs that provide
control of glycemia and reduce cardiovascular risk fac-
tors metformin is widely accepted first line agent with
additional benefits such as improvements in endothelial
dysfunction, hemostasis and oxidative stress, insulin re-
sistance, lipid profiles, and fat redistribution [2]. At the
same time, patients are becoming more interested in
traditional herbal medicines. Herbal drugs are frequently
used with conventional drugs as complementary agents,
often without medical advice [3]. Still the safety of the
herbal drugs is often overestimated. Medicinal plants
contain a plethora of active compounds that is a pre-
requisite of an increased risk of potential herb-drug
pharmacokinetic and pharmacodynamic interactions,
which, in case of diabetes, are highly possible consider-
ing lifelong treatment [4]. On the other hand, herbal
drugs may stipulate favourable pharmacological effects
and enhance the efficacy of known antihyperglycemic
drugs. A great body of evidence exists about antihyper-
glycemic and related effects of herbal medicines [5, 6].
The preclinical studies of the efficacy and safety of
herbal drugs combinations with antidiabetic medicines
have intensified recently. Several herbal preparations and
plant constituents increase efficacy of metformin on the
model of alloxan-induced diabetes [7], streptozotocine-
induced diabetes [8], in vitro and ex vivo [9].
Our efforts are focused on the verification of pharma-
cological activity of the drugs obtained from the aerial
part of Aegopodium podagraria L. (goutweed). It is a
perennial plant of the Apiaceae family indigenous to
Europe, Siberia, the Caucasus, Kazakhstan and Central
Asia mountainous regions and has been naturalized in
North America and Australia. The plant is ubiquitous,
widely used in traditional medicine, and consumed as
vegetable. The low toxicity level of goutweed prepara-
tions has been confirmed experimentally [10]. Hydro-
xycinnamic acids, flavonoids, coumarins, polyacetylene
compounds, essential oil components, micro- and
macroelements were identified in A. podagraria aerial
part. The capillary electrophoresis method was ap-
plied to establishing electrophoretic fingerprints of
leaves and stems of A. podagraria [11, 12].
Goutweed aerial part tincture and dry extract exert
protective effects in alloxan-induced diabetic mice [13],
the tincture renders hypoglycemic effect under the con-
ditions of metabolic disorders induced by fructose and
hydrochlorothiazide in rats [14], it also may cause
hypoglycemic action in intact animals [15]. A. poda-
graria preparations through different mechanisms
counteract hyperuricemia [10, 11] that is an important
link in the pathogenesis of metabolic syndrome [16]. It
is well known that kidney and liver are among the or-
gans that undergo pathological changes in diabetes, and
the additional benefits of goutweed preparations are
nephroprotective and hepatoprotective action proven in
several experimental models [10, 11, 13]. So, pharmaco-
logical properties of A. podagraria can be of great value
in metabolic syndrome and diabetes type 2 treatment.
Besides, the plant is ubiquitous and the raw material of
its aerial part is available for drug manufacturing at re-
spectively low cost, so such drugs are affordable even for
the developing countries.
At the same time, the effects of co-administration of
A. podagraria with widely used antihyperglycemic drugs,
such as metformin, have not been verified. It is expedi-
ent to investigate combination of metformin with the
tincture of A. podagraria aerial part because just this
preparation has a significant influence on glucose me-
tabolism both in alloxan-induced animals and on the
model similar to metabolic syndrome [13, 14], and it
seems reasonable to use experimental model that repro-
duce the pathogenetic mechanisms of the human meta-
bolic syndrome and type 2 diabetes [17, 18].
Therefore, the objective of this study is to determine
the influence of A. podagraria tincture and its combin-
ation with metformin on glucose and lipid metabolism
in dexamethasone-treated rats.
The dose of dexamethasone 5 mg/kg subcutaneously
was used in the study based on data demonstrating that
it leads to severe disorders of glucose metabolism in the
adult rat [19], at a close dose of 4 mg/kg significant dis-
orders of lipid metabolism are also seen [20]. As the
study was aimed at exploring the possibility of increasing
the efficacy of metformin, this drug was used at respect-
ively low dose of 50 mg/kg. Still this dose was found to
be effective on the models of glucose metabolism disor-
ders (including insulin resistance) in rats [21] and even
on the models of type 1 diabetes [7, 8]. A. podagraria
tincture was administered at a dose of 1 ml/kg intragas-
trically, since this dose produces hypoglycemic effect in
rats on the model of metabolic disorders that mimic the
human metabolic syndrome [14] but does not change
glycemia in intact animals [15].
Methods
Plant material
The aerial parts of A. podagraria L. were collected from
natural population in Kharkiv region (Ukraine) in June.
Voucher specimens of the species were identified by
Ass. Prof. Dr. S.I. Stepanova and deposited at the depart-
ment of nutriciology and pharmaceutical bromatology
(National University of Pharmacy, Kharkiv, Ukraine).
The herbal raw material was dried at room temperature
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and powdered using a standard grinding mill. Then the
powder was used for the obtaining of the tincture by
double extraction with 70 % ethyl alcohol. The plant ma-
terial and solvent were taken in 1:5 ratio, the solvent vol-
ume was increased according to the swelling index. The
solvent was divided into two parts. The plant material
was macerated in 2/3 solvent at room temperature for
five days accompanying occasional shaking and stirring.
The mixture was filtered under vacuum conditions and
maceration process was repeated under the same condi-
tions with the rest of the solvent. The obtained liquids
were combined into one, kept for two days at 4 °C, fil-
tered and brought to the calculated volume with the
solvent. Goutweed tincture is dark green liquid with a
characteristic odour. The technology is standard and
corresponds to the requirements of State Pharmacopoeia
of Ukraine, and was previously described. For the rou-
tine standardization of the obtained samples, hydroxy-
cinnamic acids total content was measured in the
tincture using UV spectrophotometry. This value was
within the range of 0.26–0.36 % [11, 15].
Drugs and chemicals
Dexamethasone solution for injection (4 mg/ml, KRKA,
d. d., Slovenia) and metformin (Sigma-Aldrich Corp.,
USA) were used in the study. Before administration met-
formin was dissolved in distilled water and alcohol was
removed from A. podagraria tincture (ex tempore). In-
sulin of short action (Actrapid, Novo Nordisk® A/S, 100
U/ml) was used for insulin tolerance test. Commercially-
available kits from Filisit-Diagnostika (Ukraine) were
used for biochemical assays. Other chemicals used were
of analytical grade.
Animals
Noninbred albino rats breeded in the Central Scientific-
Research Laboratory of National University of Pharmacy
(Ukraine) were used. Male rats with 180 to 240 g body
weight were housed in a well-ventilated animal room at
a controlled temperature and relative humidity, on a nat-
ural light–dark cycle. Food and water were supplied ad
libitum. All the experimental protocols were approved
the Bioethics Commission of the National University of
Pharmacy (Kharkiv, Ukraine) and were in accordance
with “Directive 2010/63/EU of the European Parliament
and of the Council of 22 September 2010 on the protec-
tion of animals used for scientific purposes”.
General procedures
After one week of acclimation, the rats were randomly
divided into five groups, as follows:
Group I: intact control (saline solution subcutaneously +
tap water intragastrically, n = 7);
Group II: dexamethasone, 5 mg/kg subcutaneously +
tap water intragastrically (n = 6);
Group III: dexamethasone, 5 mg/kg subcutaneously +
metformin, 50 mg/kg intragastrically (n = 6);
Group IV: dexamethasone, 5 mg/kg subcutaneously +
A. podagraria tincture, 1 ml/kg intragastrically (n = 6);
Group V: dexamethasone, 5 mg/kg subcutaneously +
metformin, 50 mg/kg intragastrically + A. podagraria
tincture, 1 ml/kg intragastrically (n = 6).
The interval between the administration of GW tinc-
ture and metformin equalled 40 min to minimize the
interaction at the level of absorption. The drugs were
administered once a day, between the 10 am and 12 pm.
Animals were fasted for 12 h before the tests and taking
final blood samples but they were allowed free access to
tap water.
The general duration of the experiment was 5 days. In-
sulin tolerance test was performed on day 3, oral glucose
tolerance test – on day 4. On day 5 of the experiment
(40 min after the drugs administration) heparinized
blood samples were drawn by exsanguination from
barbiturate-anesthetized animals. Plasma (the anticoagu-
lant heparin in vitro) was separated immediately by cen-
trifugation. Liver tissue samples were collected for
glycogen level measurement.
Insulin tolerance test
40 min after administration of the drugs, insulin was
injected at a dose of 1.0 U/kg. Blood samples for glucose
determination were obtained from a cut at the tip tail at 0
and 30 min [18].
Oral glucose tolerance test
40 min after administration of the drugs 30 % glucose
solution was given intragastrically at a dose of 3.0 g/kg.
Blood samples for glucose determination were obtained
from a cut at the tip tail at 0, 30, 60, and 120 min [18].
The total area under the blood glucose curve was calcu-
lated using the trapezoidal method, the average glycemia
value was also determined.
Biochemical analysis
Glucose concentration in all samples was measured
using the glucose oxidase method [22].
Liver glycogen was isolated through precipitation with
ethanol after alkaline hydrolysis of the liver samples and
determined as glucose after acid hydrolysis and subse-
quent neutralization [23].
Triglycerides concentration and total cholesterol con-
tent in plasma were determined using enzymatic
methods [24, 25], HDL cholesterol (HDL-C) – using
phosphotungstate-Mg2+ precipitation and enzymatic
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cholesterol assay [26], plasma total lipids level – by the
reaction with phospho-vanillin reagent [27].
Atherogenic index was calculated by using the follow-
ing formula [28]:
atherogenic index ¼ total cholesterol − HDL−Cð Þ=HDL−C
The formula of Friedewald et al. (LDL-C = total choles-
terol – HDL-C – (triacylglycerols/2.2)) was used to de-
termine LDL cholesterol (LDL-C) as it has been shown
that it is correct in rats whose HDL-C constitutes 75 %
(or more) of total serum (plasma) cholesterol [29], and
our data approached this value.
The adequacy of heparinized plasma use in the study
of the lipid metabolism values is substantiated by the
data about low basal level and activity of lipoprotein lip-
ase in rat plasma [30], and the absence of enzymatic ac-
tivity of the monomeric form of lipoprotein lipase
previously released from endothelium [31].
Statistical analysis
Medians, 25 % and 75 % percentiles (upper and lower
quartiles) were calculated as recommended for biomedical
research [32]. The traditionally used arithmetic means and
their standard errors (M±m) are also given. The compari-
son of the central tendencies of independent samples was
performed by the criterion of Mann–Whitney U (taking
into account a problematical character of multiple
comparisons in pharmacology and toxicology [33]). To
determine the relationship between the individual param-
eters, the Spearman’s correlation coefficient of ρ was used.
Results and discussion
Dexamethasone-induced model is considered a suitable
model for the investigation of drugs influencing the
pathogenetic mechanisms of type 2 diabetes and metabolic
syndrome. Diabetogenic effects are realized through
dysregulation of glucose homeostasis in liver, muscles, adi-
pose tissue. Reduction in peripheral insulin sensitivity [34]
may be compensated by the intensified pancreatic β-cells
function, but, as the latter is also directly affected by gluco-
corticoids, over time decompensation arises. In addition to
the peripheral action, steroids modulate the synthesis and
release of hormones associated with the development of
diabetes, namely glucagon, somatostatin, amylin, ghrelin,
leptin [17, 18].
We observed a significant increase in basal glycemia in-
duced by dexamethasone on day 3 of the experiment
(Fig. 1), such change was also evident on day 4, but did not
reach statistical significance because of inter-individual dif-
ferences (Table 1). The possible reason for the fasting
hyperglycemia is the well known ability of glucocorticoids
(at high doses) to promote gluconeogenesis in hepatic tis-
sue [17]. Despite of similar percent change from baseline in
the short insulin test (medians of this value equalled 40–
46 % in all groups), blood glucose level after insulin injec-
tion was significantly higher in animals treated with dexa-
methasone than in intact rats (Table 1) indicating inability
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Glycemia 30 min after insulin administration, mmol/l
Fig. 1 Influence of A. podagraria tincture and metformin on insulin sensitivity in rats receiving dexamethasone. Values are expressed as Mean ±
S.E.M; * – p < 0.05 compared to intact control; # – p < 0.02 compared to dexamethasone (untreated); ^ – p < 0.01 compared to the group
receiving metformin and A. podagraria tincture
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Metformin per se did not normalize basal level of gly-
cemia (Fig. 1, Table 1) but this value tended to return to
the normal state in animals receiving GW tincture per
se or with metformin on day 4, and on day 4 there were
statistically significant differences in basal glycemia be-
tween groups of rats receiving metformin and metfor-
min combined with GW tincture. 30 min after insulin
injection, the lowest glycemia against a background of
dexamethasone was registered in animals treated with
GW tincture and metformin combination (p < 0.02 when
compared with dexamethasone treatment only, Fig. 1).
The involvement of GW substances into the hypoglycemic
activity of the combination in the short insulin test is con-
firmed by the statistically significant difference in glycemia
between groups of rats receiving metformin per se and in
combination with GW tincture. As basal glycemia on day
3 showed a clear tendency to reduction, the percent
change from baseline in animals treated with the investi-
gated combination did not changed noticeably. The GW
tincture per se shown a decreasing trend on glycemia
(both basal and after insulin injection) which approxi-
mated to the values of rats receiving metformin and did
not differ significantly from intact control values (Fig. 1).
In the oral glucose tolerance test, in addition to the
changes in basal glycemia described above, a significant
increment of glycemia 30 min after glucose load was
seen in dexamethasone-treated rats (Table 1). The in-
crease in early postprandial glycemia due to the loss of
early insulin release is considered to play an essential
role in type 2 diabetes [35]. Besides, the changes in glu-
cose absorption are possible. According to the data [36],
the rate of appearance in plasma of gut-derived glucose
increased twice in rats treated with dexamethasone
(even at low doses). At the same time, the incomplete-
ness of glucose utilization by the tissues is reflected on
significantly increased glycemia 120 min after its intra-
gastrical administration (while in intact animals glycemia
at this time was reduced to the level lower than the basal
one). The mentioned changes led to a marked increment
of the area under the blood glucose curve as well as
average glycemia value.
The significant hypoglycemic effect of metformin was
seen only after 120 min. GW tincture per se (as well as
metformin per se) tended to normalize average glycemia
value but the effect was not statistically significant. The
lowest glycemia at baseline and 60 min after glucose
load was seen in animals receiving combined treatment
and the latter (as well as average glycemia value) had
statistically significant differences with the group receiv-
ing dexamethasone. The area under the blood glucose
curve in this group approximated to the value of intact
rats (Table 1).
The insufficiency of metformin hypoglycemic action
may be explained by the respectively low dose used.
Thus, amelioration of dexamethasone-induced hypergly-
cemia and insulin resistance in part by increasing glu-
cose disposal into skeletal muscle was proven for
metformin at significantly higher dose (250 mg/kg) [37].
Our data described above show that the possibility to
increase metformin activity (possibly improving the
safety profile and reducing the costs) by combining it
with GW tincture could be practically realized. The tinc-
ture at the dose used does not cause significant glycemia
decrease (Table 1), still it is able to enhance the effects
of metformin as basal glycemia is lowered when metfor-
min is given together with GW tincture (with
Table 1 Influence of A. podagraria tincture and metformin on the results of oral glucose tolerance test in rats receiving
dexamethasone; Mean ± S.E.M; Q50 (Q25–Q75), n = 5–6 in each group
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* – p < 0.05 compared to intact control; ** – p < 0.02 compared to intact control; *** – p < 0.01 compared to intact control
**** – p < 0.05 compared to dexamethasone (untreated); ***** – p < 0.05 compared to the group receiving metformin and A. podagraria tincture
Medians are highlighted in bold
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statistically significant differences between the groups re-
ceiving metformin per se and in combination with GW
tincture).
Hyperglycemic influence of dexamethasone was also
evident on day 5 under conditions of anaesthesia
(Table 2). The values of rats treated with metformin,
GW tincture or their combination had no statistically
significant differences compared with the data of intact
control as well as data animals receiving dexamethasone
(Table 2).
Glycogen content in the liver of dexamethasone-
treated animals increased dramatically – in 184 %. Des-
pite the possibility of glucocorticoids influence on the
insulin signalling cascade in the liver, leading to the im-
pairment of the hepatic glycogen synthesis [17] and con-
troversial data obtained in vitro (dose- and time-
dependent, biphasic effect on hepatocytes glycogen me-
tabolism) [38], in conscious animals dexamethasone is
known to stimulate liver glycogen deposition and hepatic
glucose synthesis and, as suggested by S. Baque et al.
(1996) [39], glucocorticoids may contribute to both
glycogenolysis and gluconeogenesis while sustaining in-
creased liver glucose output. Positive correlation be-
tween the level of liver glycogen and plasma glucose
registered in the group of intact animals disappeared in
dexamethasone-treated rats (Table 2). GW tincture was
not able to influence the liver glycogen level. Metformin
is usually claimed to stimulate glycogenesis, still there is
evidence that it inhibits basal glycogen synthesis and cel-
lular glycogen contents [40] and in our study this drug
tended toward the reduction of liver glycogen (per se
and in combination with the investigated tincture), and
the correlation coefficient between the level of liver
glycogen and plasma glucose approximated to the intact
group value (Table 2). The regulatory mode of action
may be assumed for metformin and the absence of the
statistically significant effect may be explained by the
low dose used.
As to the lipid metabolism changes, dexamethasone
significantly increased plasma triglycerides and tended
to raise plasma total lipids level (Fig. 2, Table 3). The in-
crement of total cholesterol content was not statistically
significant (Table 3) and was caused by the increase in
HDL and VLDL cholesterol without changes in LDL chol-
esterol concentration and atherogenic index (Table 3).
Similar data are available in the literature: dexamethasone
at a dose of 5 mg/kg perorally during 7 days influenced
only on VLDL lipoprotein level with non-significant in-
crease in total plasma cholesterol level in rats [41]. This is
consistent with the known ability of glucocorticoids to ac-
tivate the expression of several genes encoding enzymes in
triglycerides synthesis and cause lipids redistribution with
the lipolysis in adipocytes as well as triglycerides accumu-
lation in the liver [42].
Under the influence of GW tincture, but not metfor-
min, concentration of plasma triglycerides had no statis-
tically significant differences compared with the intact
control value (Fig. 2). Metformin and its combination
with the investigated herbal drug also tended towards
the normalization of the total lipids level (Table 3). The
tincture per se or with metformin caused a significant
increase in HDL cholesterol together with total plasma
cholesterol level (Table 3). Unexpectedly, the ability of
GW tincture to reduce LDL cholesterol content and the
same tendency seen against a background of metformin
were eliminated when these preparations were adminis-
tered together, and the significant differences in athero-
genic indices were seen between the groups receiving the
Table 2 Influence of A. podagraria tincture and metformin on glucose metabolism in rats receiving dexamethasone; Mean ± S.E.M;
Q50 (Q25–Q75), n = 5–7 in each group
Groups Liver glycogen,
mg/g
Glucose level in plasma
after anaesthesia, mmol/l
Coefficients of correlation between
liver glycogen and plasma glucose
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** – p < 0.02 compared to intact control; *** – p < 0.01 compared to intact control
Medians are highlighted in bold
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Table 3 Influence of A. podagraria tincture and metformin on plasma values of lipid metabolism in rats receiving dexamethasone;
















































































































* – p < 0.05 compared to intact control; ** – p < 0.02 compared to intact control; *** – p < 0.01 compared to intact control
**** – p < 0.05 compared to dexamethasone (untreated); ***** – p < 0.01 compared to dexamethasone (untreated)
****** – p < 0.05 compared to the group receiving metformin and A. podagraria tincture
******* – p < 0.02 compared to the group receiving metformin and A. podagraria tincture














Dexamethasone + metformin, 50 mg/kg
Dexamethasone + A. podagraria tincture, 1 ml/kg
Dexamethasone + metformin, 50 mg/kg + A. podagraria tincture, 1 ml/kg
Fig. 2 Influence of A. podagraria tincture and metformin on plasma triglycerides level in rats receiving dexamethasone. Values are expressed as
Mean ± S.E.M; * – p < 0.05 compared to intact control
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tincture and its combination with metformin. Spearman’s
coefficient of correlation between plasma total cholesterol
and HDL cholesterol was not statistically significant in this
group (0.26, p > 0.05), while in all other groups was within
the range of 0.83–0.98 (p < 0.05 in all cases).
Hypolipidemic properties of metformin are widely
known, still it has been shown that, in type 2 diabetes
mellitus, metformin does not affect plasma HDL choles-
terol and plasma triglycerides directly (more than might
be expected from its glucose-lowering effect) [43]. This
drug action is considered to be dose-dependent and the
absence of its significant influence at low dose is the
expected result.
The question about the active components and mech-
anisms of action of GW tincture that contribute to the
increase of metformin efficacy logically arises. Among
the substances present in the tincture, hydroxycinnamic
acids are the most possible active compounds [10–12].
Macroelements, especially potassium and magnesium,
may mediate favourable metabolic activity, still their
effect is hardly the principal one, concerning the rela-
tively short course of treatment used in our study and
lower level of these compounds extractable with ethanol
in comparison with water [12]. Protein-polysaccharide
complex is beleived to contribute to the activity of GW
extract but it is not present in sufficient quantity in the
tincture [11, 12].
A great body of evidence exists about the efficacy of
hydroxycinnamic acids and flavonoids in metabolic syn-
drome and diabetes [5, 6, 44]. Chlorogenic acid has been
recently claimed to modulate glucose and lipid metabol-
ism in vivo and to mediate the favourable effects of the
herbal extracts with well-known antidiabetic activity,
such as Morus alba leaf extract [45] as well as coffee [5].
In our study the clear tendency towards decrease in
basal glycemia was seen in animals receiving the investi-
gated tincture, and it may be linked to the inhibitory ef-
fect of chlorogenic acid on gluconeogenesis (through
the influence on glucose-6-phosphate translocase that
is verified in vitro and in diabetic animals) [46]. As the
content of hydroxycinnamic acids (in terms of chloro-
genic) in A. podagraria tincture reaches 0.36 %, the
animals received 3.6 mg/kg of this compound with the
tincture at a dose of 1 ml/kg. This dose is close to the
dose of caffeic acid 5 mg/kg investigated by K.
Karthikesan et al. [47], but somewhat lower than the
doses of chlorogenic acid used in the studies in vivo [5,
45], that corresponds to the absence of the statistically
significant hypoglycemic effect of the tincture at the
dose used.
As to the lipid metabolism influence, chlorogenic acid
is even characterized as “an anti-obesity natural mol-
ecule” [48], it is known to reduce hepatic triglycerides
level in obese mice (at respectively high dose of 30–
60 mg/kg) [5], and GW tincture exerts such effect in rats
receiving ethanol (but at higher dose of 5 ml/kg) [49]. It
has been shown recently that chlorogenic acid is one of
the active ingredients in the crude herbal drug counteract-
ing chronic ethanol-induced hepatic lipid accumulation
through MAPK/SREBP-1c-dependent and -independent
signalling pathways [50] and in vitro it increases the efflux
of total cholesterol and triacylglycerols to the hepatocytes,
inhibits HMG-CoA reductase activity [51]. In addition to
chlorogenic acid, other hydroxycinnamic acids may medi-
ate pharmacological activity of GW drugs. Furthermore,
as the dose of the tincture containing respectively low
dose of chlorogenic acid was found to increase the effects
of metformin, the other substances, most probably flavo-
noids and other phenolic compounds are involved into
pharmacological activity of the former. It is beleived that
the favourable metabolic effects of coffee are the result of
the synergistic polyphenols action, and enhancement of
caffeine and chlorogenic acid effects in combined admin-
istration was proven experimentally in the study of G.
Zheng et al. (2014) that addressed hepatic lipid metabol-
ism in mice [52]. The limitations in such studies of crude
herbal drugs and problems in preclinical data extrapola-
tion into humans were actively discussed [48]. Neverthe-
less, the synergistic mechanisms of the herbal drugs
constituents are generally recognized [53].
Besides hydroxycinnamic acids, flavonoids quercetin,
kaempferol, and their derivatives are among active sub-
stances of GW tincture [11, 12]. Health benefits of the
dietary flavonoids, including management of metabolic
syndrome, obesity, and diabetes mellitus are widely
known [6]. As dexamethasone downregulates PI3K in
rodent skeletal muscle cells and suppresses insulin-
induced translocation of GLUT4 in myotubes [17], it
may be reasonable to mention that kaempferol increases
glucose uptake and quercetin stimulates GLUT4 trans-
location and expression in skeletal muscles [6]. Further-
more, the antidiabetic potential of flavonoids has
recently been associated mainly with the modulatory ef-
fects on glucose transporters including promotion of
GLUT-4 translocation [44]. Flavonoids are able to in-
crease the expression of LDL-receptors in the liver
(quercetin) [54], suppress mRNA expression and activity
of the enzymes involved in fatty acids and triglycerides
biosynthesis in the liver (quercetin, rutin) [55], modulate
lipid metabolism through SREBP-1c, PPAR-α, and PPAR-
γ regulation and increased expression of acyl-CoA oxidase
(kaempferol) [56]. Also flavonoids are able to reduce the
level of the mediators linked to inflammation and oxida-
tive stress in the adipose tissue [6].
So there are enough data confirming the normogly-
cemic and hypolipidemic effects of GW active compo-
nents. It is much more difficult to explain the
disappearance of the influence on plasma lipoproteins
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ratio after combined administration of metformin and
the tincture. The results of this study do not allow eluci-
dating the mechanism of this interaction and further ex-
periments are required. Unfavourable pharmacokinetic
interactions between metformin and GW components
were not likely to happen because hypoglycemic activity
was present and even enhanced after combined adminis-
tration of these preparations. As described above, time
interval between these drugs administration allowed
minimizing interactions at the level of absorbtion, and
interactions at the level of metabolism are not typical for
metformin. Considering pharmacodynamical interac-
tions, it may be assumed that the different targets exist
for metformin and GW components and, taking into ac-
count the complexity of the metabolic regulatory sys-
tems, no desired effect on lipoproteins spectrum is seen
if these targets are activated simultaneously. In the
present article we have not addressed these mechanisms,
but indirect evidence can be found in the literature. It
has been shown in vitro that MPK activators including
metformin inhibit transcriptional activities of PPAR-α
and PPAR-γ [57] and activation of PPAR-α expression
that facilitates lipid clearance in the liver is considered
to mediate the efficacy of such GW active components
as kaempferol, chlorogenic and neo-chlorogenic acid in
high-fat diet-fed animals [56, 58, 59].
In general, the specific mechanisms of herbal drugs in-
teractions with conventional drugs are not studied
enough. Most of the data available are limited to the
evidence of the enhancement of metformin antihypergly-
cemic action by herbal extracts [7, 8]. In-depth study of
GW preparations interaction with metformin (especially
in the context of normoglycemic effect) also should be
addressed in future. Still there are data in the literature
that partially support our results: chlorogenic acid as
well as ferulic acid show a synergistic effect with metfor-
min on the glucose uptake by myotubes. Chlorogenic
acid increases GLUT4 expression via PI3K independent
pathway, whereas ferulic acid activity is realized
through PI3K dependent pathway [9]. Such effects of
of GW components may determine its permissive ef-
fect om the action of metformin that is becoming
possible at lower doses.
Conclusions
In conclusion, for the first time, GW tincture combined
with the respectively low dose of metformin increased
the effect on the latter on the basal glycemia in
dexamethasone-treated rats. It also showed a permissive
effect on the action of metformin in the short insulin
test indicating the improvement in the peripheral insulin
sensitivity. The efficacy of the investigated combination
was partially registered in the oral glucose tolerance test
(the lowest area under glucose curve and average glycemia
value were seen in this group). Dexamethasone-induced
dyslipidemia was partially corrected by the investigated
preparations: although the statistically significant re-
duction in LDL cholesterol content was eliminated
by simultaneous metformin administration, the de-
crease in triglycerides level and increment of HDL
cholesterol content (caused by the tincture), the ten-
dency towards the decrease in total lipids level
(resulting from metformin administration) were ob-
served against a background of the investigated
combination. In-depth study of GW preparations
interaction with metformin in the treatment of glu-
cose metabolism disorders is expedient.
Abbreviations
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